Glycosylated erythropoietin

1 . An isolated mixture of EPO molecules comprising two EPO molecules each being glycosylated with an N-linked oligosaccharide structure wherein the oligosaccharide structure present on one of the two EPO molecules is not present on the other of the two EPO molecules, the oligosaccharide structures being selected from the group consisting of:

2 . The isolated mixture of EPO molecules of claim 1 wherein the composition comprises three EPO molecules each being glycosylated with an N-linked oligosaccharide structure wherein each of the three oligosaccharide structures are different, the oligosaccharide structures being selected from the group of claim 1 .

3 . The isolated mixture of EPO molecules of claim 1 wherein the EPO molecules are human EPO molecules.

4 . The isolated mixture of EPO molecules of claim 1 wherein the two EPO molecules are pegylated.

5 . An isolated mixture of EPO molecules comprising an EPO molecule glycosylated with an oligosaccharide structure consisting of:

6 . The isolated mixture of claim 5 wherein the EPO is N-glycosylated.

7 . The isolated mixture of claim 5 wherein the EPO is human EPO.

8 . The isolated mixture of claim 5 wherein the EPO is in a pharmaceutical formulation.

9 . The isolated mixture of claim 5 wherein the EPO molecule is pegylated.

10 . An isolated mixture of EPO molecules comprising an EPO molecule glycosylated with an oligosaccharide structure consisting of:

11 . The isolated mixture of claim 10 wherein the EPO is N-glycosylated.

12 . The isolated mixture of claim 10 wherein the EPO is human EPO.

13 . The isolated mixture of claim 10 wherein the EPO is in a pharmaceutical formulation.

14 . The isolated mixture of claim 10 wherein the EPO molecule is pegylated.

15 . An isolated mixture of EPO molecules comprising an EPO molecule glycosylated with an oligosaccharide structure consisting of:

16 . The isolated mixture of claim 15 wherein the EPO is N-glycosylated.

17 . The isolated mixture of claim 15 wherein the EPO is human EPO.

18 . The isolated mixture of claim 15 wherein the EPO is in a pharmaceutical formulation.

19 . The isolated mixture of claim 15 wherein the EPO molecule is pegylated.

20 . An isolated mixture of EPO molecules comprising an EPO molecule glycosylated with an oligosaccharide structure consisting of:

21 . The isolated mixture of claim 20 wherein the EPO is N-glycosylated.

22 . The isolated mixture of claim 20 wherein the EPO is human EPO.

23 . The isolated mixture of claim 20 wherein the EPO is in a pharmaceutical formulation.

24 . The isolated mixture of claim 20 wherein the EPO molecule is pegylated.

25 . An isolated mixture of EPO molecules comprising an EPO molecule glycosylated with an oligosaccharide structure consisting of:

26 . The isolated mixture of claim 25 wherein the EPO is N-glycosylated.

27 . The isolated mixture of claim 25 wherein the EPO is human EPO.

28 . The isolated mixture of claim 25 wherein the EPO is in a pharmaceutical formulation.

29 . The isolated mixture of claim 25 wherein the EPO molecule is pegylated.

30 . An isolated mixture of EPO molecules comprising an EPO molecule glycosylated with an oligosaccharide structure consisting of:

31 . The isolated mixture of claim 30 wherein the EPO is N-glycosylated.

32 . The isolated mixture of claim 30 wherein the EPO is human EPO.

33 . The isolated mixture of claim 30 wherein the EPO is in a pharmaceutical formulation.

34 . The isolated mixture of claim 30 wherein the EPO molecule is pegylated.

35 . An isolated mixture of EPO molecules comprising an EPO molecule glycosylated with an oligosaccharide structure consisting of:

36 . The isolated mixture of claim 35 wherein the EPO is N-glycosylated.

37 . The isolated mixture of claim 35 wherein the EPO is human EPO.

38 . The isolated mixture of claim 35 wherein the EPO is in a pharmaceutical formulation.

39 . The isolated mixture of claim 35 wherein the EPO molecule is pegylated.

40 . An isolated mixture of EPO molecules comprising an EPO molecule glycosylated with an oligosaccharide structure consisting of:

41 . The isolated mixture of claim 40 wherein the EPO is N-glycosylated.

42 . The isolated mixture of claim 40 wherein the EPO is human EPO.

43 . The isolated mixture of claim 40 wherein the EPO is in a pharmaceutical formulation.

44 . The isolated mixture of claim 40 wherein the EPO molecule is pegylated.

45 . An isolated mixture of EPO molecules comprising an EPO molecule glycosylated with an oligosaccharide structure consisting of:

46 . The isolated mixture of claim 45 wherein the EPO is N-glycosylated.

47 . The isolated mixture of claim 45 wherein the EPO is human EPO.

48 . The isolated mixture of claim 45 wherein the EPO is in a pharmaceutical formulation.

49 . The isolated mixture of claim 45 wherein the EPO molecule is pegylated.

50 . An isolated mixture of EPO molecules comprising an EPO molecule glycosylated with an oligosaccharide structure consisting of:

51 . The isolated mixture of claim 50 wherein the EPO is N-glycosylated.

52 . The isolated mixture of claim 50 wherein the EPO is human EPO.

53 . The isolated mixture of claim 50 wherein the EPO is in a pharmaceutical formulation.

54 . The isolated mixture of claim 50 wherein the EPO molecule is pegylated.

55 . An isolated mixture of EPO molecules comprising an EPO molecule glycosylated with an oligosaccharide structure consisting of:

56 . The isolated mixture of claim 55 wherein the EPO is O-glycosylated

57 . The isolated mixture of claim 55 wherein the EPO is human EPO.

58 . The isolated mixture of claim 55 wherein the EPO is in a pharmaceutical formulation.

59 . The isolated mixture of claim 55 wherein the EPO molecule is pegylated.